| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lynn E DeLis. The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia? Current opinion in psychiatry. vol 21. issue 2. 2008-05-13. PMID:18332661. |
this review explores what is known about the association of cannabis with schizophrenia, its effects on the brain, and whether the brain changes known to be present in schizophrenia could be caused by cannabis and thus lead to a psychosis. |
2008-05-13 |
2023-08-12 |
Not clear |
| C Bonsack, Y Montagrin, J Favrod, S Gibellini, P Conu. [Motivational interviewing for cannabis users with psychotic disorders]. L'Encephale. vol 33. issue 5. 2008-04-22. PMID:18357854. |
cannabis is currently the most frequently used substance, and although its impact is often minimised, many data suggest it constitutes a risk for psychosis at three levels: (a) possible toxic psychosis in healthy individuals, (b) relapse of positive symptoms in schizophrenia and (c) raises the risk of schizophrenia when used early during adolescence. |
2008-04-22 |
2023-08-12 |
Not clear |
| Stanley Zammit, Gillian Spurlock, Hywel Williams, Nadine Norton, Nigel Williams, Michael C O'Donovan, Michael J Owe. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. The British journal of psychiatry : the journal of mental science. vol 191. 2008-04-15. PMID:17978319. |
genotype effects of chrna7, cnr1 and comt in schizophrenia: interactions with tobacco and cannabis use. |
2008-04-15 |
2023-08-12 |
Not clear |
| Stanley Zammit, Gillian Spurlock, Hywel Williams, Nadine Norton, Nigel Williams, Michael C O'Donovan, Michael J Owe. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. The British journal of psychiatry : the journal of mental science. vol 191. 2008-04-15. PMID:17978319. |
genetic variations might modify associations between schizophrenia and cannabis or tobacco use. |
2008-04-15 |
2023-08-12 |
Not clear |
| Stéphane Potvin, Amir Ali Sepehry, Emmanuel Sti. Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. The Australian and New Zealand journal of psychiatry. vol 41. issue 10. 2008-04-01. PMID:17828652. |
hamilton depression rating scale); and (ii) groups of schizophrenia patients were divided according to substance use disorders (alcohol, amphetamines, cannabis, cocaine, hallucinogens, heroin and/or phencyclidine). |
2008-04-01 |
2023-08-12 |
Not clear |
| Xavier Laqueille, Souheil Ghodhbane, Fethi Nacef, Zied Choubani, Mohamed Nehdi, Saïda Douki, Alain Dervau. Tobacco, alcohol and cannabis use in Tunisian patients with schizophrenia. Schizophrenia research. vol 98. issue 1-3. 2008-03-31. PMID:17689929. |
tobacco, alcohol and cannabis use in tunisian patients with schizophrenia. |
2008-03-31 |
2023-08-12 |
Not clear |
| A A Boucher, G E Hunt, T Karl, J Micheau, I S McGregor, J C Arnol. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience. vol 149. issue 4. 2008-03-28. PMID:17905522. |
cannabis use may increase the risk of developing schizophrenia by precipitating the disorder in genetically vulnerable individuals. |
2008-03-28 |
2023-08-12 |
mouse |
| Patrick D Skosnik, Sohee Park, Laura Dobbs, Wendi L Gardne. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry research. vol 157. issue 1-3. 2008-03-25. PMID:17897720. |
while cannabis is associated with positive syndrome schizophrenia (sz), it is unclear whether cannabinoids are also related to negative symptoms such as affective blunting. |
2008-03-25 |
2023-08-12 |
Not clear |
| Stéphane Potvin, Emmanuel Stip, Olivier Lipp, Marc-André Roy, Marie-France Demers, Roch-Hugo Bouchard, Alain Gendro. Anhedonia and social adaptation predict substance abuse evolution in dual diagnosis schizophrenia. The American journal of drug and alcohol abuse. vol 34. issue 1. 2008-03-19. PMID:18161645. |
twenty-four patients were diagnosed with schizophrenia and substance abuse (mainly cannabis and alcohol). |
2008-03-19 |
2023-08-12 |
Not clear |
| Louisa Degenhardt, Chris Tennant, Stuart Gilmour, David Schofield, Louise Nash, Wayne Hall, Diana McKa. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological medicine. vol 37. issue 7. 2008-01-29. PMID:17288638. |
the aim was to examine the temporal relationships over 10 months between cannabis use and symptoms of psychosis and depression in people with schizophrenia and related disorders. |
2008-01-29 |
2023-08-12 |
Not clear |
| Louisa Degenhardt, Chris Tennant, Stuart Gilmour, David Schofield, Louise Nash, Wayne Hall, Diana McKa. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological medicine. vol 37. issue 7. 2008-01-29. PMID:17288638. |
the design was a prospective study of 101 patients with schizophrenia and related disorders who were assessed monthly over 10 months on medication compliance, cannabis and other drug use, symptoms of depression and symptoms of psychosis. |
2008-01-29 |
2023-08-12 |
Not clear |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia research. vol 96. issue 1-3. 2008-01-23. PMID:17826035. |
the neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. |
2008-01-23 |
2023-08-12 |
human |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia research. vol 96. issue 1-3. 2008-01-23. PMID:17826035. |
this study examined the relationship between neuropsychological performance and three different indices of cannabis use in schizophrenia. |
2008-01-23 |
2023-08-12 |
human |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia research. vol 96. issue 1-3. 2008-01-23. PMID:17826035. |
in the schizophrenia group, 44 participants met dsm-iv criteria for lifetime cannabis abuse/dependence. |
2008-01-23 |
2023-08-12 |
human |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia research. vol 96. issue 1-3. 2008-01-23. PMID:17826035. |
within the schizophrenia group, a larger proportion of participants with lifetime cannabis abuse/dependence demonstrated better performance than those without lifetime abuse/dependence on a component of psychomotor speed. |
2008-01-23 |
2023-08-12 |
human |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophrenia research. vol 96. issue 1-3. 2008-01-23. PMID:17826035. |
in conclusion, cannabis use is associated with enhanced cognitive functioning in schizophrenia. |
2008-01-23 |
2023-08-12 |
human |
| Hans Bouwmeester, Mirjam A F M Gerrits, John G Roozemond, Jolanda Snapper, Eric Ronken, Chris G Kruse, Herman G M Westenberg, Jan M van Re. Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats. The international journal of neuropsychopharmacology. vol 10. issue 6. 2008-01-02. PMID:17076936. |
dopamine plays a key role in the pathogenesis of schizophrenia, and cannabis use has been implicated in the risk for developing schizophrenia. |
2008-01-02 |
2023-08-12 |
rat |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. The Australian and New Zealand journal of psychiatry. vol 41. issue 11. 2008-01-02. PMID:17924240. |
the neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. |
2008-01-02 |
2023-08-12 |
Not clear |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. The Australian and New Zealand journal of psychiatry. vol 41. issue 11. 2008-01-02. PMID:17924240. |
research on cannabis is especially lacking, given that worldwide it is the most commonly used illicit drug in schizophrenia, is used at higher rates in schizophrenia than in the general population, and makes its own unique contribution to the onset and prognosis of schizophrenia. |
2008-01-02 |
2023-08-12 |
Not clear |
| Carissa M Coulston, Michael Perdices, Christopher C Tennan. The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues. The Australian and New Zealand journal of psychiatry. vol 41. issue 11. 2008-01-02. PMID:17924240. |
in the present paper an overview of the neuropsychology literature on substance use in schizophrenia is presented, with special emphasis on cannabis. |
2008-01-02 |
2023-08-12 |
Not clear |